-
ARANOTE, Tumor Suppressor Gene Signature, and More in mHSPC - 27 day(s) ago
Dear readers, This week’s collection on metastatic hormone-sensitive prostate cancer (mHSPC) includes a range of new content. ARANOTE demonstrated a significant radiographic progression-free survival benefit…
-
Collection #1 - 1 month(s) ago
Commentary
-
January #1 - 2 month(s) ago
-
January Updates in mHSPC - 2 month(s) ago
Dear readers, This month, our editors are sharing the latest headlines in metastatic hormone-sensitive prostate cancer. Check out the posts below for recent updates, hand-picked…
-
What's New in Myeloma: Insights From ASH 2024 and Beyond - 3 month(s) ago
Dear readers, Although #ASH24 wrapped up only a few weeks ago, we are already so excited for the 67th meeting and enriching news in myeloma…
-
Email 1 - 3 month(s) ago
introductory
-
Recent Advances in mHSPC - 3 month(s) ago
Dear readers, This month’s roundup of headlines in metastatic hormone-sensitive prostate cancer (mHSPC) features a range of topics. First, capivasertib plus abiraterone may improve rPFS…
-
What We're Looking Forward to at AHA 2024 - 4 month(s) ago
Dear readers, The AHA Scientific Sessions 2024 kick off today in Chicago, Illinois. The meeting will present an exciting lineup of content in cardiology featuring…
-
Implementation of Triplet Therapy in mHSPC - 5 month(s) ago
Dear readers, This month, our editors want to share the most recent news and content in metastatic hormone-sensitive prostate cancer (mHSPC). First, Dr. Christopher Pieczonka…
-
Dear readers, In this series, our editors at MashupMD will share highlights in metastatic hormone-sensitive prostate cancer (mHSPC). Today, we want to bring a few…